Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06946602 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT.

StatusRecruiting
PhaseNot applicable
Started2026-01-01
View on ClinicalTrials.gov ↗

Amendment history

2026-09-10
Study Status, Contacts/Locations v2
Recruitment opened
Start dateestimated 2025-05-20→confirmed 2026-01-01
Study sitesdetails revised at 1 of 1 site
2025-05-09
Study Status, References v1
Start date2025-04-20→2025-05-20
Publicationsdetails revised at 4 of 4 entries
2025-04-19
Original filing
Elderly AML patients receiving conventional chemotherapy have poor prognosis. Allo-HSCT offers better long-term survival than chemotherapy, while high TRM limits its use. Current research focuses more on improving conditioning regimens to reduce TRM. Studies suggest Bu/Flu/Cy/ATG are safer and more effective for elderly AML haplo-HSCT, lowering TRM. However, prospective randomized trials are lacking. This study aims to compare Bu/Flu/Cy/ATG vs. Bu/Cy/ATG to determine if TRM can be reduced in elderly AML undergoing haplo-HSCT.
Trial Details
NCT Number NCT06946602
Lead Sponsor Peking University People's Hospital
Conditions AML, Elderly
Enrollment 307 participants
Start Date 2026-01-01
Primary Completion 2027-10-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-14